11.11
price down icon5.12%   -0.60
after-market After Hours: 11.11
loading
Mbx Biosciences Inc stock is traded at $11.11, with a volume of 172.11K. It is down -5.12% in the last 24 hours and up +73.59% over the past month. MBX Biosciences Inc is a clinical stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. The company designed its proprietary Precision Endocrine Peptide, or PEP, platform to overcome the key limitations of unmodified and modified peptide therapies to improve clinical outcomes and simplify disease management for patients. Its PEPs are selectively engineered to have optimized pharmaceutical properties, including extended time-action profiles and consistent drug concentrations with low peak-to-trough concentration ratios, consistent exposure to target tissues, and less frequent dosing. Its product candidates include MBX 2109, MBX 1416, and MBX 4291.
See More
Previous Close:
$11.71
Open:
$11.71
24h Volume:
172.11K
Relative Volume:
0.58
Market Cap:
$401.09M
Revenue:
-
Net Income/Loss:
$-47.20M
P/E Ratio:
-7.0977
EPS:
-1.5653
Net Cash Flow:
$-43.65M
1W Performance:
-7.42%
1M Performance:
+73.59%
6M Performance:
-51.51%
1Y Performance:
+0.00%
1-Day Range:
Value
$10.80
$11.98
1-Week Range:
Value
$10.18
$12.24
52-Week Range:
Value
$4.8069
$27.50

Mbx Biosciences Inc Stock (MBX) Company Profile

Name
Name
Mbx Biosciences Inc
Name
Phone
(317) 989-3100
Name
Address
11711 N. MERIDIAN STREET, CARMEL
Name
Employee
43
Name
Twitter
Name
Next Earnings Date
Name
Latest SEC Filings
Name
MBX's Discussions on Twitter

Compare MBX with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
MBX
Mbx Biosciences Inc
11.11 401.09M 0 -47.20M -43.65M -1.5653
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
424.99 128.84B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
527.78 65.38B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ARGX
Argen X Se Adr
549.65 39.67B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
251.15 33.82B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ONC
Beigene Ltd Adr
231.99 27.60B 3.81B -644.79M -669.77M -6.24

Mbx Biosciences Inc Stock (MBX) Upgrades & Downgrades

Date Action Analyst Rating Change
Apr-10-25 Initiated Citizens JMP Mkt Outperform
Oct-08-24 Initiated Guggenheim Buy
Oct-08-24 Initiated JP Morgan Overweight
Oct-08-24 Initiated Jefferies Buy
Oct-08-24 Initiated Stifel Buy

Mbx Biosciences Inc Stock (MBX) Latest News

pulisher
May 09, 2025

Hypoglycemia Market Poised for Notable Growth by 2032, Fueled - openPR.com

May 09, 2025
pulisher
May 05, 2025

MBX Biosciences Up 28%, Insider Buyers Are Up 19% - simplywall.st

May 05, 2025
pulisher
May 05, 2025

9,106 Shares in MBX Biosciences, Inc. (NYSE:MBX) Bought by JPMorgan Chase & Co. - Defense World

May 05, 2025
pulisher
May 05, 2025

MBX Biosciences, Inc. (NYSE:MBX) Receives Consensus Rating of “Buy” from Analysts - Defense World

May 05, 2025
pulisher
Apr 27, 2025

MBX Biosciences, Inc. (NYSE:MBX) Shares Purchased by Geode Capital Management LLC - Defense World

Apr 27, 2025
pulisher
Apr 23, 2025

JMP maintains MBX Biosciences stock $38 target, upbeat on trial data - Investing.com Australia

Apr 23, 2025
pulisher
Apr 23, 2025

Companies Like MBX Biosciences (NASDAQ:MBX) Are In A Position To Invest In Growth - Yahoo Finance

Apr 23, 2025
pulisher
Apr 22, 2025

MBX Biosciences to Participate in Citizens and RBC May Investor Conferences - The Manila Times

Apr 22, 2025
pulisher
Apr 22, 2025

MBX Biosciences Reveals Growth Strategy at Citizens and RBC Healthcare Conferences: Key Updates Coming - Stock Titan

Apr 22, 2025
pulisher
Apr 16, 2025

5,593 Shares in MBX Biosciences, Inc. (NYSE:MBX) Acquired by Corebridge Financial Inc. - Defense World

Apr 16, 2025
pulisher
Apr 13, 2025

25,000 Shares in MBX Biosciences, Inc. (NYSE:MBX) Acquired by Norges Bank - Defense World

Apr 13, 2025
pulisher
Apr 13, 2025

MBX Biosciences, Inc. (NYSE:MBX) Receives $37.40 Consensus Price Target from Brokerages - Defense World

Apr 13, 2025
pulisher
Apr 11, 2025

MBX Biosciences initiated at Market Outperform by Citizens - MSN

Apr 11, 2025
pulisher
Apr 10, 2025

Director Makes Bold Move with Major MBX Biosciences Stock Purchase - TipRanks

Apr 10, 2025
pulisher
Apr 10, 2025

JMP Securities Initiates Coverage of MBX Biosciences (MBX) with Market Outperform Recommendation - Nasdaq

Apr 10, 2025
pulisher
Apr 10, 2025

MBX Biosciences: Innovative PEP Platform and Promising Pipeline Drive Buy Rating - TipRanks

Apr 10, 2025
pulisher
Apr 10, 2025

MBX Bio stock initiated at Market Outperform by Citizens (MBX) - Seeking Alpha

Apr 10, 2025
pulisher
Apr 10, 2025

MBX Biosciences director Pescovitz buys $45,311 in stock By Investing.com - Investing.com Canada

Apr 10, 2025
pulisher
Apr 10, 2025

MBX Biosciences director Pescovitz buys $45,311 in stock - Investing.com

Apr 10, 2025
pulisher
Apr 10, 2025

MBX Biosciences initiated with an Outperform at Citizens JMP - TipRanks

Apr 10, 2025
pulisher
Apr 07, 2025

MBX Biosciences adds biotech veteran to board By Investing.com - Investing.com South Africa

Apr 07, 2025
pulisher
Apr 07, 2025

MBX Biosciences adds biotech veteran to board - Investing.com Australia

Apr 07, 2025
pulisher
Apr 07, 2025

MBX Biosciences Appoints Steve Hoerter to Board - TipRanks

Apr 07, 2025
pulisher
Apr 07, 2025

MBX Biosciences Appoints Veteran Pharmaceutical Executive Steve Hoerter to Board of Directors - GlobeNewswire

Apr 07, 2025
pulisher
Mar 30, 2025

Charles Schwab Investment Management Inc. Invests $1.72 Million in MBX Biosciences, Inc. (NYSE:MBX) - Defense World

Mar 30, 2025
pulisher
Mar 28, 2025

Bank of New York Mellon Corp Buys Shares of 23,914 MBX Biosciences, Inc. (NYSE:MBX) - Defense World

Mar 28, 2025
pulisher
Mar 26, 2025

MBX Biosciences to Participate in the 24th Annual Needham Virtual Healthcare Conference - The Manila Times

Mar 26, 2025
pulisher
Mar 26, 2025

MBX Biosciences Unveils Next-Gen Peptide Therapies: CEO Presentation at Major Healthcare Conference - Stock Titan

Mar 26, 2025
pulisher
Mar 19, 2025

MBX Biosciences Inc Reports Q4 2024 Net Loss of $15.6 Million, S - GuruFocus

Mar 19, 2025
pulisher
Mar 18, 2025

MBX Biosciences, Inc.: Promising Outlook with Strong Financials and Key Catalysts - TipRanks

Mar 18, 2025
pulisher
Mar 17, 2025

MBX Biosciences reports Q4 EPS (47c), consensus (59c) - MSN

Mar 17, 2025
pulisher
Mar 17, 2025

MBX Biosciences stock jumps 5% on clinical trial progress By Investing.com - Investing.com Australia

Mar 17, 2025
pulisher
Mar 17, 2025

MBX Biosciences stock jumps 5% on clinical trial progress - Investing.com India

Mar 17, 2025
pulisher
Mar 17, 2025

MBX Biosciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2024 - marketscreener.com

Mar 17, 2025
pulisher
Mar 17, 2025

MBX Biosciences Announces Enrollment Completion in Phase 2 Avail™ Trial of Canvuparatide; Phase 2 Trials for MBX 1416 and IND Filing for MBX 4291 Expected in 2025 - Nasdaq

Mar 17, 2025
pulisher
Mar 17, 2025

MBX Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights - GlobeNewswire

Mar 17, 2025
pulisher
Mar 17, 2025

MBX Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Recent ... - The Bakersfield Californian

Mar 17, 2025
pulisher
Mar 17, 2025

MBX Biosciences, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2024 - Marketscreener.com

Mar 17, 2025
pulisher
Mar 13, 2025

Insider Buyers At MBX Biosciences Likely Disappointed With 17% Slide - Yahoo Finance

Mar 13, 2025
pulisher
Mar 11, 2025

Rhumbline Advisers Purchases New Stake in MBX Biosciences, Inc. (NYSE:MBX) - Defense World

Mar 11, 2025
pulisher
Mar 11, 2025

Rhumbline Advisers Purchases New Holdings in MBX Biosciences, Inc. (NYSE:MBX) - The AM Reporter

Mar 11, 2025
pulisher
Mar 05, 2025

MBX Biosciences Announces Additions to Leadership Team - GlobeNewswire

Mar 05, 2025
pulisher
Mar 05, 2025

MBX Biosciences strengthens leadership team with new SVPs By Investing.com - Investing.com Canada

Mar 05, 2025
pulisher
Mar 05, 2025

MBX Biosciences Announces Additions To Leadership Team -March 05, 2025 at 08:53 am EST - Marketscreener.com

Mar 05, 2025
pulisher
Mar 05, 2025

MBX Biosciences strengthens leadership team with new SVPs - Investing.com India

Mar 05, 2025
pulisher
Mar 05, 2025

MBX Biosciences, Inc.’s Lock-Up Period Will Expire on March 12th (NYSE:MBX) - Defense World

Mar 05, 2025
pulisher
Mar 03, 2025

MBX Biosciences Completes Enrollment In Phase 2 Avail Trial Of Canvuparatide For HP - Nasdaq

Mar 03, 2025
pulisher
Mar 03, 2025

MBX Biosciences Completes Enrollment in Phase 2 Avail™ Trial of MBX 2109 (Canvuparatide) for Hypoparathyroidism - The Manila Times

Mar 03, 2025

Mbx Biosciences Inc Stock (MBX) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$65.08
price down icon 0.84%
$19.36
price down icon 0.31%
$33.15
price up icon 0.15%
$23.96
price down icon 2.80%
$92.77
price down icon 2.12%
biotechnology ONC
$231.99
price down icon 1.67%
Cap:     |  Volume (24h):